At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Durvalumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Durvalumab and Tremelimumab for Prostate Cancer. Completed, enrolled 52 participants across 11 sites.
Detailed Summary
The purpose of this study is to find out the effects of giving durvalumab alone or in combination with tremelimumab on this type of cancer. In addition, this study will look at the side effects of durvalumab when given alone or in combination with tremelimumab.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesCanada
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartDec 2016
Primary CompletionNov 2021
Study CompletionMay 2025
TodayJul 2026
First PostedJun 2, 2016
Enrollment StartDec 15, 2016
Primary CompletionNov 22, 2021
Study CompletionMay 1, 2025
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 10.1 years ago
Interventions
Durvalumabdrug
Tremelimumabdrug